Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603–1616
Article CAS PubMed PubMed Central Google Scholar
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444
Article CAS PubMed Google Scholar
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
Article CAS PubMed PubMed Central Google Scholar
Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117(5):1137–1146
Article CAS PubMed PubMed Central Google Scholar
De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13(10):613–626
Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F et al (2017) The role of prostatic inflammation in the development and progression of benign and malignant diseases. Curr Opin Urol 27(2):99–106
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and local treatment with curative intent. Eur Urol 86(2):148–163
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457
Article CAS PubMed PubMed Central Google Scholar
Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F et al (2005) Immune response in Silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 6(4):319–331
Article CAS PubMed Google Scholar
Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157(4):1301–1303
Article CAS PubMed Google Scholar
Falagario U, Selvaggio O, Carrieri G, Barret E, Sanguedolce F, Cormio L (2018) Prostatic inflammation is associated with benign prostatic hyperplasia rather than prostate cancer. J Gerontol Geriatr 66(4):178–182
Gravas S, De Nunzio C, Campos Pinheiro L,Ponce de León J, Skriapas K, Milad Z, Lombardo R, Medeiros M, Makrides P, Samarinas M, Gacci M. Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):405-410.doi: 10.1038/s41391-024-00857-5. Epub 2024 Jul 6. PMID: 38971935; PMCID: PMC12106073.
De Nunzio C, Salonia A, Gacci M, Ficarra V (2020) Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol 38(11):2771–2779
Article PubMed PubMed Central Google Scholar
Sanguedolce F, Falagario UG, Castellan P, Di Nauta M, Silecchia G, Bruno SM et al (2020) Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urol Oncol 38(10):793e19–e25
Falagario UG, Sanguedolce F, Cormio A, Ninivaggi A, Finati M, Guzzi F, Busetto GM, Bettocchi C, Castellani D, Carrieri G, Cormio L. The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy. Diagnostics (Basel). 2025 Jan 13;15(2):166. doi: 10.3390/diagnostics15020166. PMID: 39857050; PMCID: PMC11763971.
Cormio L, Lorusso F, Selvaggio O, Perrone A, Sanguedolce F, Pagliarulo V et al (2013) Noninfiltrative anesthesia for transrectal prostate biopsy: a randomized prospective study comparing lidocaine-prilocaine cream and lidocaine-ketorolac gel. Urol Oncol 31(1):68–73
Article CAS PubMed Google Scholar
Cormio L, Pagliarulo V, Lorusso F, Selvaggio O, Perrone A, Sanguedolce F et al (2012) Combined perianal-intrarectal (PI) lidocaine-prilocaine (LP) cream and lidocaine-ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy. BJU Int 109(12):1776–1780
Article CAS PubMed Google Scholar
Cormio L, Scattoni V, Lorusso F, Perrone A, Di Fino G, Selvaggio O et al (2014) Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol 32(2):341–346
Falagario UG, Abbadi A, Remmers S, Björnebo L, Bogdanovic D, Martini A et al (2023) Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open 6(9):e2332900
Article PubMed PubMed Central Google Scholar
Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C et al (2008) Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14(23):7790–7797
Article CAS PubMed PubMed Central Google Scholar
Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I (2006) Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 16(4):831–836
Suzuki K, Nakazato H, Matsui H, Hasumi M, Shibata Y, Ito K et al (2001) NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 69(4):531–537
Article CAS PubMed Google Scholar
Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114(4):560–568
Article CAS PubMed PubMed Central Google Scholar
Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y et al (2019) The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst 111(3):301–310
Madersbacher S, Sampson N, Culig Z (2019) Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. ;65(5):458–464. https://doi.org/10.1159/000496289. Epub 2019 Apr 3. PMID: 30943489
Comments (0)